english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

New cancer drugs: poorly evaluated, ineffective and overpriced

Many new cancer drugs are sold by drug companies at exorbitant prices, while their therapeutic benefit – when there is one – is usually modest.
1 May 2018

Warts: beware of acid-based wart removers

In recent years, in France and elsewhere, deep burns and necrosis, sometimes with permanent after-effects, have been reported with concentrated acid-based topical wart removers.
1 May 2018

"Preventing Overdiagnosis 2018": an international conference in Copenhagen, 20-22 August 2018

The not-for-profit group "Preventing Overdiagnosis", dedicated to "winding back the harms of too much medicine", has announced plans for its 2018 conference.
1 May 2018

Treating intermittent claudication: first encourage patients to follow a walking exercise programme

FEATURED REVIEW Some patients with lower limb peripheral artery disease experience pain while walking, due to a reduced ability to increase arterial circulation. What is the harm-benefit balance of treatments aimed at improving their walking capacity?
Full review (5 pages) available for download by subscribers.
1 April 2018

In the April issue of Prescrire International: Towards better patient care - drugs to avoid in 2018

FREE DOWNLOAD Prescrire's annual review of drugs to avoid covers all the drugs examined by Prescrire between 2010 and 2017 that are authorised in the European Union or in France. We identified 90 drugs that are more harmful than beneficial in all the indications for which they have been authorised.
1 April 2018

Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients

The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable.
1 April 2018

New drugs and indications in 2017: numerous innovations offering no progress

Marketing authorisations often granted too hastily: patients are exposed to medicines with uncertain harm-benefit balances.
1 April 2018

Prescrire's ratings of new products and indications over the past 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.
1 April 2018

Tripoliponumab: French firm Neuronodev demands withdrawal of marketing authorisation and approves 150 million euros for patients

1 April 2018

• Decline in vigilance: beware of collateral damage(s)

April Fool'sIn your dreams! Lulled by far too much information swirling around us day and night, it's no wonder we sometimes have trouble distinguishing between dreams and reality. So much so that one could almost believe a drug company would actually take the initiative to limit, and to pay for, the damage caused by one of its products. But that would be living in a dream world.
1 April 2018

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90